{"id":138823,"date":"2025-04-04T22:05:11","date_gmt":"2025-04-05T02:05:11","guid":{"rendered":"https:\/\/cardiologynownews.org\/?p=138823"},"modified":"2026-01-28T19:26:52","modified_gmt":"2026-01-29T00:26:52","slug":"shr-1918-safe-significantly-lowered-ldl-c-and-triglycerides-in-poorly-controlled-hyperlipidemia","status":"publish","type":"post","link":"https:\/\/cardiologynownews.org\/?p=138823","title":{"rendered":"SHR-1918 Safe, Significantly Lowered LDL-C and Triglycerides in Poorly Controlled Hyperlipidemia"},"content":{"rendered":"

Key Takeaways:<\/b><\/p>\n

    \n
  1. SHR-1918, an ANGPTL3 inhibitor, significantly reduced LDL cholesterol by approximately 22\u201330% and triglycerides by 52\u201363% in patients with ASCVD not optimally controlled by standard lipid-lowering therapy.<\/span><\/li>\n
  2. The safety profile of SHR-1918 was favorable, with predominantly mild adverse events comparable to placebo, suggesting strong potential for clinical application to address residual cardiovascular risk.<\/span><\/li>\n<\/ol>\n

    In a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial (NCT06109831), the novel angiopoietin-like 3 (ANGPTL3) monoclonal antibody SHR-1918 demonstrated significant reductions in LDL cholesterol (LDL-C) and triglycerides (TG) in patients with moderate or higher risk atherosclerotic cardiovascular disease (ASCVD) whose lipid levels remained suboptimal despite standard lipid-lowering therapies. The findings, presented at the American College of Cardiology Annual Scientific Session (ACC.25) and simultaneously published in the <\/span>Journal of the American College of Cardiology<\/span><\/i><\/a>, underscore the potential for ANGPTL3 inhibition as a potential therapeutic strategy to reduce residual cardiovascular risk.<\/span><\/p>\n

    The study enrolled 333 participants in 35 medical centers in China who had not achieved optimal LDL-C control despite receiving statins (99.1% of participants) and other lipid-lowering therapies such as cholesterol absorption inhibitors (12.0%) or PCSK9 inhibitors (0.9%). Patients were randomized to receive subcutaneous SHR-1918 (150 mg, 300 mg, or 600 mg every 4 weeks [Q4W], or 600 mg every 8 weeks [Q8W]) or placebo for 16 weeks, followed by an extended open-label phase lasting up to 56 weeks.<\/span><\/p>\n

    At week 16, SHR-1918 produced dose-dependent and statistically significant reductions in LDL-C compared with placebo, achieving reductions of 21.7% (150 mg Q4W), 27.3% (300 mg Q4W), 29.9% (600 mg Q4W), and 22.5% (600 mg Q8W) (all p<0.0001). Significant triglyceride reductions were also observed, ranging from 51.7% to 63.2% across SHR-1918 dosing groups (all P<0.0001). The percentage of patients achieving LDL-C targets at week 16 ranged from 59.1% to 71.2% in the SHR-1918 groups, significantly higher than placebo (approximately 31%).<\/span><\/p>\n

    Safety analyses indicated SHR-1918 was well tolerated, with adverse event rates comparable between treatment groups and placebo. Treatment-related adverse events were predominantly mild and occurred infrequently. The most common treatment-related events included injection-site reactions (3.4%), hyperuricemia (2.6%), and mild elevations in creatine phosphokinase and liver enzymes, none of which were associated with long-term safety concerns.<\/span><\/p>\n

     <\/p>\n

    Dr. Xiaojie Xe and Dr. Jian\u2019an Wang, the lead investigators of the study wrote, \u201cThe core advantage of SHR-1918 lies in its unique target of action by inhibiting ANGPTL-3 while enhancing the activity of LPL and EL, which achieves dual regulation of LDL-C and TG. The findings of this study support that SHR-1918 could be a novel treatment option for patients with moderate or higher risk of ASCVD who have not achieved optimal lipid control and need additional lipid reduction beyond statins and other lipid-lowering therapies.\u00a0<\/span><\/p>\n

    Further research, including larger Phase 3 studies, will be essential to fully establish the clinical efficacy and long-term safety of SHR-1918.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

    Key Takeaways: SHR-1918, an ANGPTL3 inhibitor, significantly reduced LDL cholesterol by approximately 22\u201330% and triglycerides by 52\u201363% in patients with ASCVD not optimally controlled by standard lipid-lowering therapy. The safety profile of SHR-1918 was favorable, with predominantly mild adverse events comparable to placebo, suggesting strong potential for clinical application to address residual cardiovascular risk. In […]<\/p>\n","protected":false},"author":40616,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[898,8],"tags":[899,45,47,185],"ppma_author":[1070],"class_list":{"0":"post-138823","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-acc-2025","7":"category-news","8":"tag-acc-2025","9":"tag-conference","10":"tag-featured","11":"tag-news","12":"author-joseph-kim-md"},"authors":[{"term_id":1070,"user_id":40616,"is_guest":0,"slug":"joseph-kim-md","display_name":"Joseph Kim MD","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/bf0879bf0ca450025acf71d7345cf24be4748f67f7b0c6423d186a5765c5cda9?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/users\/40616"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=138823"}],"version-history":[{"count":1,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138823\/revisions"}],"predecessor-version":[{"id":138825,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138823\/revisions\/138825"}],"wp:attachment":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=138823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=138823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=138823"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=138823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}